- Home
- SFBS vs RARE Comparison
SFBS vs RARE Comparison
Compare SFBS & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFBS
- RARE
- Stock Information
- Founded
- SFBS 2005
- RARE 2010
- Country
- SFBS United States
- RARE United States
- Employees
- SFBS N/A
- RARE N/A
- Industry
- SFBS Major Banks
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- SFBS Finance
- RARE Health Care
- Exchange
- SFBS Nasdaq
- RARE Nasdaq
- Market Cap
- SFBS 4.1B
- RARE 3.3B
- IPO Year
- SFBS 2014
- RARE 2014
- Fundamental
- Price
- SFBS $72.93
- RARE $37.14
- Analyst Decision
- SFBS Hold
- RARE Strong Buy
- Analyst Count
- SFBS 1
- RARE 15
- Target Price
- SFBS $84.00
- RARE $90.53
- AVG Volume (30 Days)
- SFBS 173.7K
- RARE 1.1M
- Earning Date
- SFBS 07-14-2025
- RARE 07-31-2025
- Dividend Yield
- SFBS 1.84%
- RARE N/A
- EPS Growth
- SFBS 20.55
- RARE N/A
- EPS
- SFBS 4.40
- RARE N/A
- Revenue
- SFBS $477,064,000.00
- RARE $590,689,000.00
- Revenue This Year
- SFBS $25.60
- RARE $18.94
- Revenue Next Year
- SFBS $13.11
- RARE $28.93
- P/E Ratio
- SFBS $16.44
- RARE N/A
- Revenue Growth
- SFBS 17.21
- RARE 33.46
- 52 Week Low
- SFBS $58.51
- RARE $29.59
- 52 Week High
- SFBS $101.37
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- SFBS 44.99
- RARE 52.29
- Support Level
- SFBS $71.27
- RARE $36.01
- Resistance Level
- SFBS $73.74
- RARE $40.19
- Average True Range (ATR)
- SFBS 1.39
- RARE 1.47
- MACD
- SFBS -0.24
- RARE 0.06
- Stochastic Oscillator
- SFBS 29.96
- RARE 49.92
About SFBS ServisFirst Bancshares Inc.
Servisfirst Bancshares Inc is a bank holding company whose business is conducted by its wholly owned subsidiary, ServisFirst Bank. Through the bank, it offers various banking services to individual and corporate customers in Birmingham, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. Its various products and service offerings include commercial, consumer, and other loans; accepting deposits; providing electronic banking services, such as online and mobile banking, including remote deposit capture; delivering treasury and cash management services; and providing banking services to other financial institutions. The company operates as a single reportable segment, with a majority of its revenue being derived from the business of banking.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.